Lung Ambition Alliance lanciert das Ziel, die Überlebensrate von fünf Jahren bei Lungenkrebs bis 2025 zu verdoppeln
July 08, 2019 11:24 ET
|
AstraZeneca
LONDON, July 08, 2019 (GLOBE NEWSWIRE) -- Die International Association for the Study of Lung Cancer (IASLC), Guardant Health, die Global Lung Cancer Coalition (GLCC) und AstraZeneca gaben heute die...
Lung Ambition Alliance launches with goal to double five-year survival in lung cancer by 2025
July 08, 2019 02:00 ET
|
AstraZeneca
LONDON, July 08, 2019 (GLOBE NEWSWIRE) -- Today, the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca...
AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting
April 16, 2018 17:05 ET
|
AstraZeneca
Phase Ib Study 006 long-term follow-up shows clinical activity in PD-L1 ≥25% and <25% groups in 2nd-line non-small cell lung cancer Phase I Study 10 data shows clinical activity with combination...
AstraZeneca Does Not Recommend or Endorse Unsolicited 'Mini-Tender' Offer
March 22, 2004 11:12 ET
|
AstraZeneca
London, UK, March 22, 2004 (PRIMEZONE) --
AstraZeneca Does Not Recommend or Endorse
Unsolicited "Mini-Tender" Offer
AstraZeneca PLC announced today that it has...